Results of early phase clinical trials with single-agent PI3K inhibitors have shown only modest activity in NSCLC with innate and acquired resistance to PI3K pathway inhibition a major hurdle to overcome in the development of these drugs. The gene discussed is PIK3CD; the disease is non-small cell lung carcinoma.